Cargando…

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Inhibition of the extracellular signal-regulated kinases ERK1 and ERK2 (ERK1/2) offers a promising therapeutic strategy in cancers harboring activated RAS/RAF/MEK/ERK signaling pathways. Here, we describe an orally bioavailable and selective ERK1/2 inhibitor, ASN007, currently in clinical developmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Portelinha, Ana, Thompson, Scott, Smith, Roger A., Da Silva Ferreira, Mariana, Asgari, Zahra, Knezevic, Andrea, Seshan, Venkatraman, de Stanchina, Elisa, Gupta, Sandeep, Denis, Louis, Younes, Anas, Reddy, Sanjeeva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324497/ https://www.ncbi.nlm.nih.gov/pubmed/34337566 http://dx.doi.org/10.1016/j.xcrm.2021.100350

Ejemplares similares

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors
por: Lai, Lick Pui, et al.
Publicado: (2022)

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
por: Portelinha, Ana, et al.
Publicado: (2023)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
por: Mondello, Patrizia, et al.
Publicado: (2017)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
por: Liu, Yuxuan, et al.
Publicado: (2018)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Atorvastatin inhibits insulin synthesis by inhibiting the Ras/Raf/ERK/CREB pathway in INS-1 cells
por: Sun, Hongxi, et al.
Publicado: (2016)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Targeting Cadherin-17 Inactivates Ras/Raf/MEK/ERK Signaling and Inhibits Cell Proliferation in Gastric Cancer
por: Lin, Zhaohu, et al.
Publicado: (2014)

Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf
por: Kawabata, Noriyuki, et al.
Publicado: (2016)

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
por: Kinsey, Conan G., et al.
Publicado: (2019)

Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
por: Chen, Shi‐Lu, et al.
Publicado: (2019)

Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway
por: Rao, Qing, et al.
Publicado: (2022)

Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa
por: Jafari, Meryem, et al.
Publicado: (2022)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

Interferon- α 2b reduces phosphorylation and activity of MEK and ERK through a Ras / Raf -independent mechanism
por: Romerio, F, et al.
Publicado: (2000)

DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras–ERK pathway, is required for myogenic differentiation
por: Yokoyama, Takashi, et al.
Publicado: (2007)

By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis
por: Gao, Jiujiao, et al.
Publicado: (2015)

Upregulated Ras/Raf/ERK1/2 signaling pathway: a new hope in the repair of spinal cord injury
por: Liu, Tao, et al.
Publicado: (2015)

The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer
por: Huang, Jianbo, et al.
Publicado: (2017)

CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways
por: Schulte, Simone Laura, et al.
Publicado: (2016)

FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway
por: Li, Kun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q5es1vg7ucoqf4jsmailp292ak